Protective effects of bezafibrate against elaidic acid-induced accumulation of lipid droplets in monocytic cells

Current Research in Translational Medicine

Volumn 65, Issue 1, 2017, Pages 20-30

  Haj Ahmed, S ^a   Kharroubi, W ^a   Zarrouk, A ^a,b   Brahmi, F ^c   Nury, T ^b   Lizard, G ^b   Hammami, M ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b INSERM   (France)

^c UNIVERSITY OF BEJAIA   (Algeria)

Author keywords

Bezafibrate; Elaidic acid; Lipid droplets; Oleic acid; Palmitic acid

Indexed keywords

BEZAFIBRATE; CD36 ANTIGEN; ELAIDIC ACID; FAT DROPLET; MONOCYTE CHEMOTACTIC PROTEIN 1; OLEIC ACID; PALMITIC ACID; SUPEROXIDE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPLASM; HUMAN; HUMAN CELL; LIPID COMPOSITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; U-937 CELL LINE; ATHEROSCLEROTIC PLAQUE; BLOOD; CASE CONTROL STUDY; CELL PROTECTION; CHEMICALLY INDUCED; CORONARY ARTERY DISEASE; DRUG EFFECT; FOAM CELL; METABOLISM; PATHOLOGY;

BEZAFIBRATE; CASE-CONTROL STUDIES; CORONARY DISEASE; CYTOPROTECTION; FOAM CELLS; HUMANS; LIPID DROPLETS; MONOCYTES; OLEIC ACIDS; PLAQUE, ATHEROSCLEROTIC; U937 CELLS;

EID: 85008640148     PISSN: None     EISSN: 24523186     Source Type: Journal    
DOI: 10.1016/j.retram.2016.08.001     Document Type: Article

References (68)

1. Mensink, R.P., Metabolic and health effects of isomeric fatty acids. Curr Opin Lipidol 16 (2005), 27–30.
2. Stender, S., Astrup, A., Dyerberg, J., Ruminant and industrially produced trans fatty acids: health aspects. Food Nutr Res, 2008, 52.
3. Mozaffarian, D., Aro, A., Willett, W.C., Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 63 (2009), 5–21.
4. Mozaffarian, D., Trans fatty acids – effects on systemic inflammation and endothelial function. Atheroscler Suppl 7 (2006), 29–32.
5. Pietinen, P., Ascherio, A., Korhonen, P., Hartman, A.M., Willett, W.C., Albanes, D., et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol 145 (1997), 876–887.
6. Oomen, C.M., Ocké, M.C., Feskens, E.J., van Erp-Baart, M.A., Kok, F.J., Kromhout, D., Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 357 (2001), 746–751.
7. Mozaffarian, D., Katan, M.B., Ascherio, A., Stampfer, M.J., Willett, W.C., Trans fatty acids and cardiovascular disease. N Engl J Med 354 (2006), 1601–1613.
8. Chardigny, J.M., Destaillats, F., Malpuech-Brugère, C., Moulin, J., Bauman, D.E., Lock, A.L., et al. Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study. Am J ClinNutr 87 (2008), 558–566.
9. Jakobsen, M.U., Overvad, K., Dyerberg, J., Heitmann, B.L., Intake of ruminant trans fatty acids and risk of coronary heart disease. Int J Epidemiol 37 (2008), 173–182.
10. Jaipersad, A.S., Lip, G.Y., Silverman, S., Shantsila, E., The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 63 (2014), 1–11.
11. Liu, Y., Hultén, L.M., Wiklund, O., Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. ArteriosclerThrombVasc Biol 17 (1997), 317–323.
12. Trogan, E., Fayad, Z.A., Itskovich, V.V., Aguinaldo, J.G., Mani, V., Fallon, J.T., et al. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. ArteriosclerThrombVasc Biol 24 (2004), 1714–1719.
13. Elangbam, C.S., Tyler, R.D., Lightfoot, R.M., Peroxisome proliferator-activatedreceptors in atherosclerosis and inflammation – an update. Toxicol Pathol 29 (2001), 224–231.
14. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998), 790–793.
15. Neve, B.P., Corseaux, D., Chinetti, G., Zawadzki, C., Fruchart, J.C., Duriez, P., et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 (2001), 207–212.
16. Ringseis, R., Wen, G., Saal, D., Eder, K., Conjugated linoleic acid isomers reduce cholesterol accumulation in acetylated LDL-induced mouse RAW264.7macrophage-derived foam cells. Lipids 43 (2008), 913–923.
17. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., Evans, R.M., PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998), 241–252.
18. Berger, J., Moller, D.E., The mechanisms of action of PPARs. Annu Rev Med 53 (2002), 409–435.
19. Lizard, G., Deckert, V., Dubrez, L., Moisant, M., Gambert, P., Lagrost, L., Induction of apoptosis in endothelial cells treated with cholesterol oxides. Am J Pathol 148 (1996), 1625–1638.
20. Lemaire-Ewing, S., Prunet, C., Montange, T., Vejux, A., Berthier, A., Bessède, G., et al. Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol 21 (2005), 97–114.
21. Rothe, G., Valet, G., Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J Leukoc Biol 47 (1990), 440–448.
22. Macho, A., Hirsch, T., Marzo, I., Marchetti, P., Dallaporta, B., Susin, S.A., et al. Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. J Immunol 158 (1997), 4612–4619.
23. Prunet, C., Montange, T., Véjux, A., Laubriet, A., Rohmer, J.F., Riedinger, J.M., et al. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A 69 (2006), 359–373.
24. Klinkner, A.M., Bugelski, P.J., Waites, C.R., Louden, C., Hart, T.K., Kerns, W.D., A novel technique for mapping the lipid composition of atherosclerotic fatty streaks by en face fluorescence microscopy. J Histochem Cytochem 45 (1997), 743–753.
25. Vejux, A., Kahn, E., Dumas, D., Bessède, G., Ménétrier, F., Athias, A., et al. 7 Ketocholesterol favors lipid accumulation and colocalizes with Nile Red positive cytoplasmic structures formed during 7-ketocholesterol-induced apoptosis: analysis by flow cytometry. FRET biphoton spectral imaging microscopy, and subcellular fractionation. Cytometry A 64 (2005), 87–100.
26. Folch, J., Lees, M., Sloane Stanley, G.H., A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226 (1957), 497–509.
27. Mensink, R.P., Zock, P.L., Kester, A.D., Katan, M.B., Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77 (2003), 1146–1155.
28. Calder, P.C., Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 668 (2011), 50–58.
29. Thompson, A.K., Minihane, A.M., Williams, C.M., Trans fatty acids, insulin resistance and diabetes. Eur J Clin Nutr 65 (2011), 553–564.
30. Kavanagh, K., Jones, K.L., Sawyer, J., Kelley, K., Carr, J.J., Wagner, J.D., et al. Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring) 15 (2007), 1675–1684.
31. Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., Flier, J.S., TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116 (2006), 3015–3025.
32. Suganami, T., Nishida, J., Ogawa, Y., A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. ArteriosclerThrombVasc Biol 25 (2005), 2062–2068.
33. Naruszewicz, M., Daniewski, M., Nowicka, G., Kozłowska-Wojciechowska, M., Trans-unsaturated fatty acids and acrylamide in food as potential atherosclerosis progression factors. Based on own studies. Acta Microbiol Pol 52 (2003), 75–81.
34. Schwartz, E.A., Zhang, W.Y., Karnik, S.K., Borwege, S., Anand, V.R., Laine, P.S., et al. Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler ThrombVasc Biol 30 (2010), 802–808.
35. Håversen, L., Danielsson, K.N., Fogelstrand, L., Wiklund, O., Induction of pro-inflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 202 (2009), 382–393.
36. Holzer, R.G., Park, E.J., Li, N., Tran, H., Chen, M., Choi, C., et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147 (2011), 173–184.
37. Beilman, G., Pathogenesis of oleic acid-induced lung injury in the rat: distribution of oleic acid during injury and early endothelial cell changes. Lipids 30 (1995), 817–823.
38. Gonçalves-de-Albuquerque, C.F., Silva, A.R., Burth, P., de Moraes, I.M., Oliveira, F.M., Younes-Ibrahim, M., et al. Oleic acid induces lung injury in mice through activation of the ERK pathway. Mediators Inflamm, 2012, 2012, 956509.
39. Ballard-Croft, C., Wang, D., Sumpter, L.R., Zhou, X., Zwischenberger, J.B., Large-animal models of acute respiratory distress syndrome. Ann Thorac Surg 93 (2012), 1331–1339.
40. Ang, S.F., Sio, S.W., Moochhala, S.M., MacAry, P.A., Bhatia, M., Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation. J Immunol 187 (2011), 4778–4787.
41. Martins de Lima, T., Gorjão, R., Hatanaka, E., Cury-Boaventura, M.F., Portioli Silva, E.P., Procopio, J., et al. Mechanisms by which fatty acids regulate leucocyte function. Clin Sci (Lond) 113 (2007), 65–77.
42. Kroemer, G., Galluzzi, L., Brenner, C., Mitochondrial membrane permeabilization in cell death. Physiol Rev 87 (2007), 99–163.
43. Hua, J., Ma, X., Webb, T., Potter, J.J., Oelke, M., Li, Z., Dietary fatty acids modulate antigen presentation to hepatic NKT cells in non-alcoholic fatty liver disease. J Lipid Res 51 (2010), 1696–1703.
44. Andersson, A., Nälsén, C., Tengblad, S., Vessby, B., Fatty acid composition ofskeletal muscle reflects dietary fat composition in humans. Am J Clin Nutr 76 (2009), 1222–1229.
45. Cnop, M., Hannaert, J.C., Hoorens, A., Eizirik, D.L., Pipeleers, D.G., Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 50 (2001), 1771–1777.
46. Ricchi, M., Odoardi, M.R., Carulli, L., Anzivino, C., Ballestri, S., Pinetti, A., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24 (2009), 830–840.
47. Stachowska, E., Dołegowska, B., Chlubek, D., Wesołowska, T., Ciechanowski, K., Gutowski, P., et al. Dietary trans fatty acids and composition of human atheromatous plaques. Eur J Nutr 43 (2004), 313–318.
48. Li, Z., Berk, M., McIntyre, T.M., Gores, G.J., Feldstein, A.E., The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47 (2008), 1495–1503.
49. Chinetti, G., Lestavel, S., Fruchart, J.C., Clavey, V., Staels, B., Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 92 (2003), 212–217.
50. Mascaró, C., Acosta, E., Ortiz, J.A., Marrero, P.F., Hegardt, F.G., Haro, D., Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 273 (1998), 8560–8563.
51. Ghosh, S., Natarajan, R., Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun 284 (2001), 1065–1070.
52. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Torra, I.P., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001), 53–58.
53. Feldstein, A.E., Canbay, A., Angulo, P., Taniai, M., Burgart, L.J., Lindor, K.D., et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003), 437–443.
54. Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V. Jr., Ory, D.S., et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100 (2003), 3077–3082.
55. De Caterina, R., Bernini, W., Libby, P., Fatty acid structural requirements for the inhibition of endothelial activation. Circulation 94:Suppl. I (1996), I–I102.
56. Shimabukuro, M., Zhou, Y.T., Levi, M., Unger, R.H., Fatty acid-induced beta cellapoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95 (1998), 2498–2502.
57. Collot-Teixeira, S., Martin, J., McDermott-Roe, C., Poston, R., McGregor, J.L., CD36 and macrophages in atherosclerosis. Cardiovasc Res 75 (2007), 468–477.
58. Massaro, M., Carluccio, M.A., Bonfrate, C., Siculella, L., Lazzerini, G., Bernini, W., et al. The double bond in unsaturated fatty acids is the necessary and sufficient requirement for the inhibition of expression of endothelial leukocyte adhesion molecules through interference with nuclear factor-kappaB activation. Lipids 34 Suppl. (1999), S213–S214.
59. −/− mouse by conjugated linoleic acid. Biochem Soc Trans 31 (2003), 1075–1079.
60. Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blanchard, S.G., Brown, P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3 (1999), 397–403.
61. Endemann, G., Stanton, L.W., Madden, K.S., Bryant, C.M., White, R.T., Protter, A.A., CD36 is a receptor for oxidized low-density lipoprotein. J Biol Chem 268 (1993), 11811–11816.
62. Nicholson, A.C., Hajjar, D.P., CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol 41 (2004), 139–146.
63. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., Glass, C.K., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998), 79–82.
64. Jiang, C., Ting, A.T., Seed, B., PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998), 82–86.
65. Ericsson, C.G., Hamsten, A., Nilsson, J., Grip, L., Svane, B., de Faire, U., Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996), 849–853.
66. Eacho, P.I., Foxworthy, P.S., Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA. Biochem Biophys Res Commun 157 (1988), 1148–1153.
67. Gregersen, N., Bross, P., Andresen, B.S., Genetic defects in fatty acidbeta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis andgenotype-phenotype relationships. Eur J Biochem 271 (2004), 470–482.
68. Issemann, I., Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990), 645–650.